PUNE, India, May 13, 2016 /PRNewswire-iReach/ -- Cystic Fibrosis Pipeline Market Companies Involved in Therapeutics
Development are Actelion Ltd, Akari Therapeutics, Plc, Alaxia SAS, AlgiPharma AS, AmpliPhi Biosciences Corporation, Arcturus Therapeutics, Inc, Aridis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Calista Therapeutics, Inc., Carolus Therapeutics, Inc., Celtaxsys, Inc., Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals, Inc., Corbus pharmaceuticals, Inc., CSA Biotechnologies LLC, Cyclacel Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Editas Medicine, Inc., Errant Gene Therapeutics, LLC, Galapagos NV, GlaxoSmithKline Plc, Grifols, S.A., Grupo Praxis Pharmaceutical SA, Horizon Pharma Plc, Insmed Incorporated, Invion Limited, JHL Biotech, Inc., Kamada Ltd., La Jolla Pharmaceutical Company, Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc., Mast Therapeutics, Inc., Merck & Co., Inc., Microbion Corporation, Mucokinetica Ltd., NanoBio Corporation, Nivalis Therapeutics, Inc., Nostrum Pharmaceuticals, LLC, Novabiotics Limited, Novartis AG, OSE Pharma SA, Parion Sciences, Inc., Pfizer Inc., Pharmaxis Limited, PhaseBio Pharmaceuticals, Inc., Polyphor Ltd., Progenra, Inc., ProMetic Life Sciences Inc., ProQR Therapeutics N.V., Protalix BioTherapeutics, Inc., Proteostasis Therapeutics, Inc., PTC Therapeutics, Inc., Pulmatrix, Inc., Raptor Pharmaceutical Corp., ReveraGen BioPharma, Inc., Savara Inc., Serendex Pharmaceuticals A/S, Shionogi & Co., Ltd., Shire Plc, Synovo GmbH, TGV-Laboratories, The International Biotechnology Center (IBC) Generium, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Xenetic Biosciences (UK) Limited, Zambon Company S.p.A.
Photo - http://photos.prnewswire.com/prnh/20160513/367261
The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
Inquire more about this research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=542540
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
Complete research report of 406 pages with TOC is avaialble at http://www.rnrmarketresearch.com/cystic-fibrosis-pipeline-review-h1-2016-market-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Media Contact: Ritesh Tiwari, RnR Market Research, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research